Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.

Moore, Kathleen N

Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. [electronic resource] - Cancer Dec 2010 - 5407-14 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural

0008-543X

10.1002/cncr.25480 doi


Aged
Antibiotics, Antineoplastic--therapeutic use
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Clinical Trials, Phase III as Topic
Disease-Free Survival
Doxorubicin--therapeutic use
Endometrial Neoplasms--drug therapy
Female
Humans
Middle Aged
Randomized Controlled Trials as Topic
Recurrence
Salvage Therapy
Survival Analysis
Time Factors